Nektar Therapeutics (NASDAQ: NKTR)
Nektar Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Nektar Therapeutics Company Info
Nektar Therapeutics is a global biopharmaceutical company focused on the discovery and development of novel therapies that selectively modulate the immune system to treat autoimmune disorders. It applies its deep understanding of immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly selective medicines with optimal therapeutic benefit.
News & Analysis
Why Nektar Therapeutics Stock Is Crashing Today
The company is throwing in the towel on its lead pipeline program.
Why Nektar Therapeutics Stock Is Imploding Today
A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.
Why Nektar Therapeutics Stock Plunged Today
The company's Q3 revenue was lower than expected.
3 Stocks Wall Street Thinks Will Soar 50% or More in 2021
These stocks have one obvious thing in common.
2 Biotechs Battling Against Kidney Cancer
New combination trials bring hope for patients and investors.
Here's How Nektar Therapeutics Performed in Q4
The biotech topped Wall Street estimates, but the real focus was on its pipeline.
FDA Advisory Committee Slams Nektar's New Opioid Drug
In a 27-0 shutout, the advisory committee voted against approval of the company's pain drug, oxycodegol.
Why Nektar Therapeutics Stock Is Sinking Today
The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.